diabetes tirzepatide Dosing: vs Weight Loss Diabetes: Tirzepatide May Lower Risk

Empowering healthcare through accessibility and innovation

Tirzepatide was approved in 2022 as Mounjaro for diabetes, and in 2024 as Zepbound for obesity, with exclusivity running until May 2027

Discover how it compares to injectable weight-loss medications and if it's right for you.

List of the top Latin America Glucagon-like Peptide-1 (GLP-1) Agonists companies based on extensive research conducted by Mordor Intelligence analysts and expert advisors that identified these brands to be the leaders and major players in the Latin America Glucagon-like Peptide-1 (GLP-1) Agonists sector.

If your doctor recommends the switch from Zepbound to Wegovy, its important to follow a personalized plan for discontinuing Zepbound and starting Wegovy.

We look at how much Mounjaro costs without insurance and discuss the best places to buy Mounjaro without insurance.